Display options
Cite
Li M, Czyszczon EA, Reineke JJ, et al. Delineating intracellular pharmacokinetics of paclitaxel delivered by PLGA nanoparticles. Drug Deliv Transl Res. 2013;3(6):551-61doi: 10.1007/s13346-013-0162-y.
Li, M., Czyszczon, E. A., Reineke, J. J., Brigido, M., & Borrachero, A. B. (2013). Delineating intracellular pharmacokinetics of paclitaxel delivered by PLGA nanoparticles. Drug delivery and translational research, 3(6), 551-61. https://doi.org/10.1007/s13346-013-0162-y
Li, Mingguang, et al. "Delineating intracellular pharmacokinetics of paclitaxel delivered by PLGA nanoparticles." Drug delivery and translational research vol. 3,6 (2013): 551-61. doi: https://doi.org/10.1007/s13346-013-0162-y
Li M, Czyszczon EA, Reineke JJ, Brigido M, Borrachero AB. Delineating intracellular pharmacokinetics of paclitaxel delivered by PLGA nanoparticles. Drug Deliv Transl Res. 2013 Dec;3(6):551-61. doi: 10.1007/s13346-013-0162-y. PMID: 25786375.
Copy Download .nbib Format: NLM
Share it on

Drug Deliv Transl Res. 2013 Dec;3(6):551-61. doi: 10.1007/s13346-013-0162-y.

Delineating intracellular pharmacokinetics of paclitaxel delivered by PLGA nanoparticles.

Drug delivery and translational research

Mingguang Li, Emilia Anna Czyszczon, Joshua James Reineke, Brigido, Borrachero

Affiliations

  1. Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 48202, USA.

PMID: 25786375 DOI: 10.1007/s13346-013-0162-y

Abstract

Although many studies have shown that drug delivery and efficacy can be improved by nano-sized drug carriers, we understand little regarding their pharmacokinetics (PK). PK calculations for drugs delivered by carriers are more complex than those for drug-only solutions. The overall PK depends on many factors, including drug-release rate and the PK of both the drug itself and the carrier. We built a mathematical model to describe the intracellular PK of paclitaxel delivered by nanoparticles. Paclitaxel was incorporated into poly (lactic-co-glycolic acid) nanoparticles, which were chemically labeled with a fluorescence probe for quantification. PK profiles of drug alone, nanoparticles alone, and drug delivered by nanoparticles were studied in human breast cancer MCF7 cells. Simulated results from the model were similar to observed data, indicating that the model was properly developed. The model clearly and quantitatively represented the effects of relative factors, such as drug dose, drug-release kinetics, and nanoparticle PK, on the PK of paclitaxel delivered by nanoparticles. We also used this model to estimate the intracellular drug-release rate, which was found to be slightly slower than the in vitro release rate in this study. This mathematical model could be used to provide guidelines to design, evaluate, and optimize nano-sized drug carriers.

References

  1. Trends Biotechnol. 2008 Oct;26(10):552-8 - PubMed
  2. Mol Pharm. 2013 Jun 3;10(6):2183-9 - PubMed
  3. Mol Cancer Ther. 2004 Oct;3(10):1301-10 - PubMed
  4. Toxicol Lett. 2011 Aug 10;205(1):55-61 - PubMed
  5. J Control Release. 2003 Jan 9;86(1):33-48 - PubMed
  6. J Control Release. 2002 Oct 4;83(2):273-286 - PubMed
  7. Anticancer Drugs. 1992 Aug;3(4):311-21 - PubMed
  8. Math Biosci Eng. 2011 Apr;8(2):325-54 - PubMed
  9. Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51 - PubMed
  10. Cancer Chemother Pharmacol. 2004 Dec;54(6):514-24 - PubMed
  11. Nanoscale. 2011 Aug;3(8):3291-9 - PubMed
  12. Acta Biomater. 2007 Nov;3(6):838-50 - PubMed
  13. J Biomater Sci Polym Ed. 2006;17(3):247-89 - PubMed
  14. Int J Nanomedicine. 2012;7:1345-56 - PubMed
  15. Methods Mol Biol. 2012;926:369-82 - PubMed
  16. Adv Drug Deliv Rev. 2013 Jan;65(1):121-38 - PubMed
  17. Biotechnol Bioeng. 2008 Dec 1;101(5):1072-82 - PubMed
  18. J Pharmacol Exp Ther. 2000 Jun;293(3):761-70 - PubMed
  19. ACS Nano. 2010 Nov 23;4(11):6303-17 - PubMed
  20. Nature. 2003 Mar 6;422(6927):37-44 - PubMed
  21. Adv Biochem Eng Biotechnol. 2011;125:251-80 - PubMed

Publication Types